B Cell Design

B Cell Design is a French biotechnology company specializing in the development and production of high-quality monoclonal antibodies with human Fc regions. Utilizing its patented transgenic mouse platform, GAME™, the company designs and produces chimeric and humanized antibodies (including IgA, IgG, IgM, and IgE isotypes) that serve as highly reliable, standardized alternatives to disease-state plasma (DSP) for the in vitro diagnostics (IVD) industry. In addition to its diagnostic reagents, B Cell Design has historically pursued therapeutic programs, including a preclinical-stage mucosal immunotherapy (monoclonal IgA1) targeting gastrointestinal and colorectal cancers, as well as mucosal vaccines for HIV. Acquired by Inoviem Scientific in 2021, B Cell Design operates as an active subsidiary within the Aton Group (formerly Hybrigenics/DMS Biotech).